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Hepatocellular carcinoma (HCC) most often develops in patients with underlying liver disease characterized by chronic nonresolving
inflammation. Tumor-associated macrophages (TAMs) are one of the most abundant immune cell populations within the tumoral
microenvironment. As key actors of cancer-related inflammation, they promote tumor growth by suppression of effective
anticancer immunity, stimulation of angiogenesis, and tissue remodeling. Therefore, they have become an attractive and promising
target for immunotherapy. The heterogeneity of TAM subtypes and their origin and dynamic phenotype during the initiation and
progression of HCC has been partially unraveled and forms the base for the development of therapeutic agents. Current
approaches are aimed at decreasing the population of TAMs by depleting macrophages present in the tumor, blocking the
recruitment of bone marrow-derived monocytes, and/or functionally reprogramming TAMs to antitumoral behavior. In this
review, the preclinical evolution and hitherto clinical trials for TAM-targeted therapy in HCC will be highlighted.
1. Introduction
Hepatocellular carcinoma (HCC) lesions usually arise in
patients with underlying liver cirrhosis, characterized by a
chronic, dysregulated inflammatory environment that predis-
poses to cancer initiation. In chronic liver diseases, a predom-
inantly proinflammatory state switches to persistent systemic
inflammation and immune cell stimulation but with impair-
ment of specific immune responses such as phagocytosis
and antigen-presenting ability, a condition which is called
cirrhosis-associated immune dysfunction. This is an impor-
tant differencewith an acute inflammatory response, regarded
as protective and beneficial in the acute setting of liver damage
and resolution. Chronic inflammation drives indeed a mal-
adaptive tissue repair reaction and eventually results in the
development of dysplastic nodules and cancer [1–4].
The central functions of macrophages during chronic
liver diseases include the perpetuation of chronic inflamma-
tion and hepatocyte injury, activation of hepatic stellate cells
with subsequent fibrogenesis, and support of tumor develop-
ment by providing cytokines, chemokines, growth factors,
and matrix metalloproteases, all of which are factors that
favor angiogenesis and tumor cell proliferation and protec-
tion from cancer cell apoptosis and metastasis [5, 6]. Thus,
hepatic macrophages provide a tumor-prone inflammatory
microenvironment and at the same time respond to tumor
and other stromal cell-derived signals to actively facilitate
HCC progression [1, 7, 8]. Tumor-associated macrophages
(TAMs) also stimulate tumor growth by acting as immune
suppressor cells of the adaptive system. Not only do TAMs
exhibit generally low antigen-presenting and costimulating
capacity but they also actively support cancer cells to evade
antitumor immunity by secreting anti-inflammatory cyto-
kines and activating T cell checkpoint blockade. In this regard,
tumor-infiltrating monocytes in HCC express high level of
programmed cell death-ligand 1 (PD-L1) that binds with
PD-1 on CD8+ T cells and suppresses antitumoral cytotoxic
T cell responses [9–11]. This overall immune-suppressive
Hindawi
Journal of Immunology Research
Volume 2018, Article ID 7819520, 9 pages
https://doi.org/10.1155/2018/7819520
effect is reinforced by cross-talk with other important
immune cells in the tumoral microenvironment, such as
myeloid-derived suppressor cells (MDSC) and regulatory
T cells (Tregs). Besides t5he suppression of cytotoxic T cells,
MDSC and Tregs contribute to the dysfunctional state of
dendritic cells (DCs) [1, 12–14].
Since TAMs influence various aspects of cancer progres-
sion, novel strategies to treat HCC are aimed at targeting
tumor-promoting macrophages. New therapeutic develop-
ment is an urgent unmet need as options are still limited
for patients with advanced HCC or earlier stage progressing
upon or patients unsuitable for locoregional therapies. Now-
adays, cancer immunotherapy mainly focuses on immune
checkpoint inhibitors. After the observed efficacy in other
solid tumors, clinical trials are currently ongoing to evaluate
the utility in patients with HCC. Based on promising data in
the phase I/II CheckMate-040 trial, immune therapy with
nivolumab (anti-PD-1 antibody) has received FDA approval
in second-line treatment [15]. However, only 20% of patients
are responsive. In solid tumors, recent studies suggest that
the efficacy could be enhanced using coordinated strategies
to counteract the TAM-dependent impairment of immune
adaptive responses [16–18].
Although the clinical application of a TAM-targeted
approach still has to be determined, a number of experimen-
tal preclinical studies have shown promising effects. Most
studies involve other solid tumors and are described else-
where [19–24]. In this review, the preclinical progress and
limited clinical trials affecting TAMs in HCC therapy will
be highlighted. Furthermore, the encountered challenges
are discussed in relation to fundamental insights into the het-
erogeneity of TAM subtypes and their origin and dynamic
phenotype and function during the initiation and progression
of HCC. Lastly, we elaborate on the potential contributive
effect of combinational therapies with clinically used thera-
pies such as sorafenib and immune checkpoint inhibitors.
2. Definition and Origin of TAMs in HCC
Liver macrophages consist of ontogenically distinct popu-
lations, namely, the resident Kupffer cells (KCs) and
monocyte-derived macrophages (Mo-Mfs). Kupffer cells are
self-renewing and nonmigratory phagocytes. They originate
from yolk sac-derived specific progenitor cells that seed the
liver during embryogenesis. In the tumoral microenviron-
ment, chemokines secreted by malignant and stromal cells
recruit bone marrow-derived Ly-6chi monocytes. These infil-
trating monocytes subsequently give rise to large numbers of
Mo-Mfs. Monocyte-derived macrophages further differenti-
ate and can replace and acquire a phenotype that is almost
indistinguishable from resident KCs under specific circum-
stances [25–30]. After infiltration, Mo-Mfs even seem to
acquire the ability to proliferate [27]. It is however unclear
if they are able to sustain the number of TAMs in tumor
lesions independently from recruitment. As a result of this
continuous transition, the compartment of hepatic myeloid
cells consists of subtypes of macrophages in a different state
of differentiation. Each state is associated with stereotypic
alterations in cell surface marker expression, which can be
used for identification. In many studies, CD68 is used as an
indicator for tissue macrophages, but this marker is not suf-
ficiently specific. More recently, two markers were proposed
to distinguish between Mo-Mfs and KCs. Clec4F and Tim4
are expressed by KCs but absent from infiltrating Mo-Mfs.
Additionally, these markers can be used to discriminate
between KCs and recently differentiated Mo-KCs as the latter
do not express Tim4 in the first week postdifferentiation.
However, with time, Mo-KCs will also gain expression of
Tim4 [27, 28].
It is not clear to what extent TAMs are derived from
tissue-resident liver cells or only represent infiltrating bone-
marrow derived Mo-Mfs. In most reports, macrophages
present in the tumoral microenvironment are considered
and classified as “tumor-associated macrophages.” Although
KCs were initially thought to be only involved in antitumor
immunity, there is substantial evidence that suggests that
KCs are part of the TAM population and enhance tumor pro-
gression [3, 31–33]. KCs are triggered by damage-associated
molecular patterns (DAMPs) released from damaged liver
cells and pathogen-associated molecular patterns (PAMPs),
mostly derived from the gut due to alterations in gut micro-
biota composition and/or increased intestinal permeability.
The liver is supplied with blood via the portal vein from the
intestinal tract and via hepatic arteries from the blood circu-
lation. As such, KCs in the liver sinusoids are exposed to
bacteria and associated toxins from the bloodstream [34].
DAMPs and PAMPs interact with pattern recognition recep-
tors (PRR) on KC or directly on activating inflammasomes
[34]. For example, the interaction of lipopolysaccharide
(LPS) with Toll-like receptor 4 (TLR-4) on KCs showed stim-
ulation of cancer-promoting signaling pathways in mice [35].
3. Phenotype and Function of TAMs in HCC
Defining TAMs as one population has limitations as shown
in the contradictory results of prognostic studies, summa-
rized in Table 1. This is mostly due to an overgeneralized
definition of TAMs and indicates the need for further subdi-
vision according to their polarization. Polarization refers
to how macrophages have been activated as they can rapidly
adapt to their phenotype according to signals derived from
the hepatic microenvironment. Macrophages have been
assigned a classically activated (proinflammatory) M1 state
triggered by interferon-γ and/or lipopolysaccharide or an
alternatively activated (anti-inflammatory) M2 state induced
by IL-4. This traditional nomenclature however is derived
from in vitro studies and does not represent chronic
inflammation or the complex tumoral microenvironment.
Moreover, the expression and secretory profile of macro-
phage subsets are not dichotomous and can differ accord-
ing to the model and method of inducing polarization.
There is also considerable difference between mouse and
human cells in terms of molecules associated with macro-
phage polarization [28, 36–39].
The pro- and anti-inflammatory paradigm leads to the
confusing assumption that in an inflammation-related
tumor, an M2 phenotype would be beneficial. However,
during tumor progression in HCC, macrophage function is
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skewed from M1 to M2 phenotype [10, 40]. An anti-
inflammatory phenotype does not result in the resolution of
inflammation but refers to the immune-deficient and
immune-suppressive state of these macrophages and conse-
quently immune evasion of cancer cells. On the other hand,
a proinflammatory phenotype does not refer to inflamma-
tory damage in an acute setting but represents a coordinated
immune attack of tumor cells. Thus, the M1/M2 model is too
simplistic to describe the polarization of liver macrophages in
cancer. Currently, TAMs are most often defined as M1-like
(leading to antitumor responses and cytotoxicity) or M2-like
(tumorpromotion and suppressionof effective adaptive immu-
nity) cells, taking into account the relative proportion between
both characteristics as they often simultaneously express
markers of both ends of the continuum [36]. The polarization
of macrophages not only depends on the disease stage but also
differs between tumoral nodules or within different areas of
the same tumor. In human HCC, for example, most of the
macrophages that are localized perivascularly are more M1-
like compared to the M2-like TAM in hypoxic areas [25, 38].
4. TAM-Targeted Therapy in HCC
Current approaches for TAM-targeted therapy are aimed at
decreasing the population of TAMs by eliminating TAMs
present in the tumor, blocking recruitment of bone
marrow-derived monocytes, and/or reprogramming TAM
polarization to antitumoral behavior (Figure 1).
4.1. Preclinical Studies. In the following section, only preclin-
ical studies in mouse models using agents with a direct effect
on TAMs in HCC will be discussed and are summarized in
Table 2. Gene therapy or knockout models are beyond the
scope of this review.
4.1.1. Depletion of TAMs. Liposomes are artificially prepared
vesicles that undergo phagocytosis by macrophages after
Table 1: Prognosis of HCC according to TAM identification and polarization. Immunohistochemical staining for CD68, CD86 (M1), or
CD163 and CD206 (M2) is frequently used to quantify and classify TAMs [38, 41]. Expression of the used tissue markers was determined
by immunohistochemical staining. Serum sCD163 levels were measured by ELISA. Defining TAMs as solely CD68+ cells gives
contradictory prognostic results. When however TAMs are subdivided for location (intra- or peritumoral) and polarization (M1- or M2-like
cells), a more distinct prognostic value can be attributed. Moreover, it becomes clear from the presented studies that the presence of M2-like
oriented TAMs results in a poor prognostic outcome and intratumoral M1-like TAMs correlate with good prognosis.
Author Number of patient samples Type of sample Marker Definition Prognosis
Li et al. [42] 101 Intratumoral CD68+ TAM Poor
Ding et al. [43] 137 Intratumoral CD68+ TAM Poor
Kuang et al. [11] 262 Peritumoral CD68+ TAM Poor
Zhang et al. [44] 149 Peritumoral CD68+ TAM Poor
Zhou et al. [45] 213 Intratumoral CD68+ TAM Poor
Wu et al. [33] 71 Intratumoral CD68+ TAM Poor
Minami et al. [46] 105 Intratumoral CD68+ TAM Poor
Liao et al. [47] 387 Intratumoral CD68+ TAM Not related
Dong et al. [48] 253 Intratumoral CD68+ TAM Not related
Yeung et al. [49] 93 Intratumoral CD68+ TAM Good
Yeung et al. [49] 93 Peritumoral CD68+ TAM Poor
Li et al. [50] 302 Intratumoral CD68+ TAM Good
Liao et al. [47] 387 Intratumoral CD16+ M2-like Poor
Waidmann et al. [51] 267 Serum sCD163+ M2-like Poor
Minami et al. [46] 105 Intratumoral CD163+ M2-like Poor
Yeung et al. [49] 93 Peritumoral CD163+ M2-like Poor
Dong et al. [48] 253 Intratumoral CD206+ M2-like Poor
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Figure 1: Origin of TAMs in the hepatic tumoral
microenvironment and related TAM-targeted strategies.
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injection. They can be loaded with clodronate (a bisphospho-
nate used for osteoporosis) which induces apoptosis of
macrophages after intracellular release from the liposomes.
Administration of clodronate- (Cl2MDP) encapsulated
liposomes partially depleted TAMs (defined as F4/80- and
CD68-positive cells on immunohistochemical staining),
resulting in reduced tumor growth in a murine Hepa1-6
cell-transplanted tumor model. Not only was the total
amount of TAMs reduced but also the number of M2-like
TAMs in tumors of liposome-treated mice was significantly
lower than that in tumors of untreated mice. In contrast,
the number of M1 TAMs was not significantly affected.
According to the authors, these results suggest that after
depleting the majority of TAMs, the remaining macrophages
might undergo a phenotypical transition [52].
Selective depletion of only tumor-promoting macro-
phages, not just all cells with phagocyting capacity, is an
encountered difficulty in TAM-targeted therapy. An exces-
sive reduction of nontumoral macrophages might lead to
safety concerns when concomitant infections occur. The
use of macrophage subset-specific markers might provide a
solution and has successfully been used in the field of imag-
ing where KC-specific [53] or TAM-specific targeting by
nanobodies coupled to SPECT or PET tracers allowed
KC-specific and M2-like TAM-specific imaging, respectively
[54]. Further research is warranted to see if this approach
could be translated to pharmaceutical development. It must
be emphasized that TAMs are strongly connected with other
immune and stromal cells in the microenvironment and it is
not clear to what extent other cells will compensate for their
function after depletion.
4.1.2. Inhibiting Recruitment of Monocytes. The chemokine
C-C motif ligand 2 (CCL2, also referred to as monocyte che-
moattractant protein 1 or MCP-1) and the corresponding
CCL2-CCR2 signaling axis are important targets to inhibit
the recruitment of monocytes. Treatment with a CCR2
antagonist inhibited HCC tumor growth in different murine
models. The therapy reduced the infiltration of blood
Ly6Chigh inflammatory monocytes, subsequently lowered
the number of TAMs (CD11b- and F4/80-positive cells) in
the HCC lesions, and reduced most of the cytokines or che-
mokines produced by M2-like TAMs (CD206-positive cells).
Moreover, the reduced number of remaining TAM shifted
towards M1 phenotype. The CCR2 antagonist also supported
tumor-infiltrated CD8+ T cells by blocking TAM-mediated
immunosuppression [55, 56]. In addition, Teng et al. showed
the tumor-inhibiting effect of a CCL2 neutralizing antibody
by reducing the population of inflammatory myeloid cells
in a HCC mouse model [57]. Although several chemokines
are involved in attracting monocytes and targeting one path-
way might not completely eliminate recruitment, blocking
the CCL2-CCR2 seems to be effective in the inhibition of
HCC growth.
Infiltration of monocytes is considered the most impor-
tant source of TAMs in the tumoral microenvironment. It
is still unclear if TAMs are able to sustain their number
(or least partially) in tumors by proliferation independently
from recruitment or how long TAMs survive in the
tumoral microenvironment. Related to this issue, effective
timing to start inhibiting recruitment of monocytes can
be debated as during early stages, TAMs can also exert an
antitumoral function.
4.1.3. Reprogramming Polarization of TAMs. Oral adminis-
tration of baicalin, a natural flavonoid present in several
medicinal plants, inhibited growth of HCC lesions in an
orthotopic mouse model by initiating TAM reprogramming
to an M1-like phenotype with proinflammatory cytokine
production. Coculturing of HCC cells with baicalin-treated
macrophages resulted in reduced proliferation and motility
in vitro [58].
Colony-stimulating factor-1 (CSF-1) and its receptor,
CSF-1R, regulate the differentiation and function of macro-
phages. CSF-1R blockade by a competitive inhibitor signifi-
cantly delayed tumor growth in murine xenograft models.
The compound inhibited the proliferation of macrophages
in vitro, but macrophage infiltration was not decreased
in vivo. Thus, the effect is not mediated by TAM depletion.
Gene expression profiling showed that TAMs in the treated
tumors are polarized towards an M1-like phenotype [59].
An imbalance towards M1-like macrophages might theo-
retically be harmful by inducing toxicity and inflammatory
conditions. In the mentioned studies, no toxic effects were
observed but further studies are necessary.
4.1.4. Blocking the Downstream Effect of TAM Products.
TAMs represent a major paracrine IL-6 source during HCC
progression, and autocrine IL-6 contributed significantly to
HCC initiation from HCC progenitor cells. Blockade of
IL-6 signaling using tocilizumab, an anti-IL-6 receptor anti-
body approved by the FDA for the treatment of rheumatoid
arthritis, was able to inhibit TAM-stimulated activity of
cancer stem cells in vitro and in vivo [60].
4.2. Preclinical Therapy Affecting TAMs with Currently Used
Clinical Therapies. Sorafenib, an antiangiogenic oral multiki-
nase inhibitor, is currently the standard first-line systemic
treatment approved by theUS Food andDrugAdministration
(FDA) and European Medicines Agency (EMA) for patients
with advanced HCC. Preclinical studies show that sorafenib
interferes with the polarization of TAMs and their cytokine
production. In a HepG2 HCC cell line, sorafenib inhibited
polarizedmacrophage-induced epithelial-mesenchymal tran-
sition and migration of HCC cells [61]. Administration of
sorafenib reduced M2-like TAMs, inhibited their immune-
suppressive effect, and stimulated antitumor natural killer
(NK) cell responses in both HCC models [62]. In addition,
Sprinzl et al. [63] demonstrated a decrease in CD163 serum
concentration in 21 patients with HCC during treatment with
sorafenib. This finding suggests that Sorafenib suppressedM2
activation in HCC patients, since soluble sCD163 is shedded
into serumby activatedmacrophages and can serve as an indi-
cator to follow M2 macrophage responses [51, 64]. Together,
these findings indicate that macrophage modulation contrib-
utes to the anticancer activity of sorafenib.
Interestingly, the combination of sorafenib with
TAM-targeting agents such as clodronate-loaded liposomes
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and zoledronic acid (another bisphosphonate used for the
treatment of bone metastasis) augmented the inhibitory
effect of sorafenib on tumor angiogenesis, growth, and
metastasis in HCC xenograft mouse models [65]. A phase
II study of sorafenib combined with zoledronic acid in
advanced HCC has been conducted (NCT01259193), but
no results have been published yet. Besides depletion of
macrophages, nitrogen-containing bisphosphonates (such
as zoledronic acid) activate γδ T cells, potentiating their
antitumor function. This immunomodulatory effect of
zoledronic acid on γδ T cells is exerted through direct or
indirect interaction induced by TAMs that endocytose
bisphosphonate-encapsulated liposomes [66, 67]. Not only
is this effect shown for sorafenib but also the combination
of locoregional therapy such as transarterial chemoembo-
lization (TACE) and zoledronic acid treatment showed
enhanced therapeutic efficacy with inhibition of TAM
infiltration (F4/80+) and tumor angiogenesis in a rat HCC
model [68]. The enhanced efficacy of sorafenib together with
a CCR2 antagonist to inhibit monocyte infiltration has been
shown in a murine HCC model [56].
The effect of checkpoint blockade immunotherapy on
TAMs has been shown for other solid tumors, but no data
are available in HCC. Blockade of PD-1 in vivo reduced
tumor growth and extended the survival in a colorectal
cancer mouse model by polarization of TAMs to a
phagocytic phenotype [69]. The efficacy of anticytotoxic
T lymphocyte-associated antigen 4 (CTLA-4) monoclonal
antibodies in a melanoma mouse model and humans is code-
fined by elimination of regulatory T cells by TAM targeting
via antibody-dependent cellular cytotoxicity [16–18, 45].
Also, in a pancreatic cancer mouse model, the combination
of depleting M2-like TAMs and repolarization towards anti-
tumoral behavior through blockage of CSF-1/CSF-1R and
immunotherapy (PD-1 and CTLA-4 antagonists) reduced
tumor progression [18].
4.3. Clinical Trials. Glypican-3 is a proteoglycan that is
attached to the cell surface and plays an important role in
cellular growth, differentiation, and migration. Glypican-3
is highly expressed in HCC tissue and correlates with poor
prognosis. It is considered a tumor-derived carcinoembryo-
nic antigen. For example, expression of glypican-3 was
associated with upregulation of CCL5, CCL3, and CSF-1 in
a HCC xenograft model [70], all of which are chemokines
that have been shown to enhance the recruitment of TAMs.
Glypican-3 antibodies have been tested in small phase I trials
for advanced HCC with promising results (in 13 and 20
patients, respectively). The antibody is well tolerated, and
preliminary antitumor activity shows a threefold prolonga-
tion of the median time to progression in treated patients
with advanced HCC (Child–Pugh A or B cirrhosis) [71, 72].
No phase II trials are currently registered with glypican-3
antibodies for HCC.
5. Conclusion
The tumor-promoting cascade of initial injury recognition,
amplification of inflammation by monocyte recruitment,
and context-dependent differentiation into functionally dis-
tinct macrophage populations in the liver offers different
approaches for therapeutic interventions in HCC. Although
the clinical application of TAM-targeted therapy is still in
its infancy, a number of preclinical studies in HCC murine
models have shown promising results. The most important
obstacles to overcome are firstly the specificity of depleting
only protumoral TAMs while not affecting (or even enhanc-
ing) antitumor immunity and secondly the perfect balance of
their polarization towards antitumoral behavior without tox-
icity and side effects. The observed potential contributive
effect of immune checkpoint inhibitors on solid tumors and
currently used clinical therapies for HCC such as sorafenib
is encouraging and must be further explored.
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